Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06929481 · ClinicalTrials.gov registry record · NA
Screening With a DNA Blood Test to Address Colorectal Cancer Inequities
A NA study, sponsored by University of California, San Diego.
- Active
- Registry status
- NA
- Development phase
- 340
- Enrollment target
NCT06929481: Active NA study, sponsored by University of California, San Diego.
NCT06929481 is a NA study that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 340 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06929481, a NA study, is active but no longer recruiting, sponsored by University of California, San Diego.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 340 participants
- Enrollment target
Study Summary
Colorectal cancer (CRC) screening participation is suboptimal and associated with inequities in CRC outcomes by race/ethnicity and socioeconomic position. A novel, cell free DNA (cfDNA) blood test has potential to increase participation, but has not been studied in groups at highest risk for adverse CRC outcomes. Among patients age-eligible for colorectal cancer screening, not up-to-date, we propose a 2-arm, pragmatic, randomized controlled trial comparing offers of standard screening options (at home fecal immunochemical test (FIT) or colonoscopy) vs. offers of expanded options (at home FIT, colonoscopy, or in clinic cfDNA plus at home FIT), set at a large Federally Qualified Health Center serving individuals at increased risk for inequities in CRC outcomes. Results will inform guideline and policy makers on whether cfDNA should be supported as a screening option, and support planning for a large-scale trial examining impact of a cfDNA option for screening on CRC and advanced neoplasia detection.
Primary Outcome
A single primary outcome measure, screening completion within 60 days of enrollment, is planned. The outcome measure will be defined as the proportion of people enrolled meeting inclusion criteria who complete a colorectal cancer screening test within 60 days of enrollment. The definition of colorectal cancer screening test completion includes exposure to a fecal immunochemical test, colonoscopy, or cell free DNA test. The outcome measure will be computed for the standard versus expanded option
Interventions
- DEVICE Cell free DNA (cfDNA) blood test
- OTHER At home Fecal Immunochemical Test (FIT) or Colonoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2026-07 |
| Phase | NA |
What the registry record for NCT06929481 still lists
NCT06929481 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 2 interventions - of which Cell free DNA (cfDNA) blood test is the first listed.
NCT06929481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06929481 about?
NCT06929481 is a clinical study titled "Screening With a DNA Blood Test to Address Colorectal Cancer Inequities". Colorectal cancer (CRC) screening participation is suboptimal and associated with inequities in CRC outcomes by race/ethnicity and socioeconomic position. A novel, cell free DNA (cfDNA) blood test has potential to increase participation, but has not been studied in groups at highest risk for adverse...
What is the current status of trial NCT06929481?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 340 participants. The study started on 2025-04-28. Estimated completion is 2026-07.
What interventions are being tested in trial NCT06929481?
The interventions under investigation include: Cell free DNA (cfDNA) blood test (DEVICE), At home Fecal Immunochemical Test (FIT) or Colonoscopy (OTHER).
Who is sponsoring clinical trial NCT06929481?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06929481's enrollment target sits among peer trials
340 302nd of 2000 higher than 1,696 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI